Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
Key Points
Key Points
Patients with cancer are significantly more likely to develop VTE than people without cancer and experience higher rates of VTE recurrence and bleeding complications during VTE treatment.
Comprehensive management of VTE in patients with cancer includes both the identification of patients who are most likely to benefit from pharmacologic prophylaxis, as well as effective treatment to reduce the risk of VTE recurrence and mortality.
The current update adds apixaban as an option for the treatment of VTE in patients with cancer, and addresses recent evidence regarding direct factor Xa inhibitors for extended postoperative thromboprophylaxis.
Treatment
Treatme...
...pitalized patients who have active maligna...
Hospitalized patients who have act...
...tine pharmacologic thromboprophylaxis shou...
...utine pharmacologic thromboprophylaxis...
High-risk outpatients with cancer (Khorana sc...
...ts with multiple myeloma receiving th...
...ith malignant disease undergoing major surg...
...rophylaxis with UFH or LMWH should be comme...
...chanical methods may be added to ph...
...men of pharmacologic and mechanical prophylaxis ma...
...armacologic thromboprophylaxis for patients und...
...ed pharmacologic thromboprophylaxis for up to 4 w...
...ients who are candidates for extended pharma...
...ed) Alternatively, patients may be off...
...) Initial anticoagulation may involve...
...For long-term anticoagulation, LMWH, edoxa...
...with LMWH, direct factor Xa inhibitors, o...
...expert opinion in the absence of randomized t...
...a vena cava filter may be offered as an...
...h primary or metastatic central nervous system ma...
...idental PE and deep vein thrombosis s...
...tment of isolated subsegmental PE or splanchnic o...
Anticoagulant use is not recommended to improve su...
...substantial variation in risk of VTE betwee...
...sts and members of the oncology team should...
...ng off-label use in guideline recomm...
...tive Model for Chemotherapy-associated VTE...